Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Optinose

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
- Evidenced-based expert algorithm separates EDS-FLU, marketed as XHANCE®, from standard intranasal steroid sprays, recommending it for patients with nasal polyps whose symptoms persist after using... 
Tickers OPTN
From PR Newswire
New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day
Sufferers often confused on the cause of symptoms and should "go deeper" because nasal polyps are often undiagnosed 
Tickers OPTN
From PR Newswire
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life 
Tickers OPTN
From PR Newswire
Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application (NDA) for XHANCE (previously... 
From Business Wire News Releases
OptiNose Raises $37 Million in Series D Funding Led by Fidelity
OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company with... 
From Business Wire News Releases
Michael F. Marino Joins OptiNose as Chief Legal Officer
OptiNose™ today announced the appointment of Michael F. Marino as Chief Legal Officer. Mr. Marino is a seasoned executive and legal advisor with more than 15 years of experience advising public and... 
From Business Wire News Releases
OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
OptiNose™ today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for the investigational new product OPN-375. OptiNose is seeking... 
From Business Wire News Releases
OptiNose Appoints Keith Goldan as Chief Financial Officer
OptiNose today announced the appointment of Keith A. Goldan as Chief Financial Officer (CFO). Mr. Goldan brings to the company more than 25 years of executive finance and operational leadership in... 
From Business Wire News Releases
CORRECTING and REPLACING OptiNose to Present at the 35th Annual J.P. Morgan Healthcare Conference
Please replace the release due to revisions to the company boilerplate. 
From Business Wire News Releases
New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients
According to new research presented today at the American Rhinologic Society Annual Meeting, an estimated 28 million Americans are currently suffering from the symptoms of Chronic Rhinosinusitis (CRS)... 
From Business Wire News Releases
CORRECTING and REPLACING OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis (CRS)
In the original release, there were two instances (second bullet under NAVIGATE II and first bullet under EXHANCE-12) where dosage amounts of EDS-FLU read 371 µg twice daily; these should have read 372... 
From Business Wire News Releases
OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment for Acute Migraine Using Bi-Directional™ Breath Powered® Technology
OptiNose, a privately-held specialty biopharmaceutical company, today announced that its licensing partner, Avanir Pharmaceuticals, Inc. has reported that the U.S. Food & Drug Administration (FDA)... 
From Business Wire News Releases
OptiNose to Present at the 34th Annual J.P. Morgan Healthcare Conference
OptiNose today announced that the company will present at the 34th annual J.P. Morgan Healthcare Conference. CEO Peter Miller will discuss the Company's recent milestones, pipeline and strategy for... 
From Business Wire News Releases
OptiNose Closes New Round of Financing
OptiNose, a specialty biopharmaceutical company, announced today that it has closed a new round of financing providing up to $30M in additional capital. Since completing its previous financing round in... 
From Business Wire News Releases
OptiNoseTM Announces Positive Results of Second Phase III Pivotal Trial for OPN-375
OptiNose today announced positive results from a second phase III pivotal trial, NAVIGATE I. This follows and helps both to confirm and support the positive results from a first pivotal trial, NAVIGATE... 
From Business Wire News Releases
OptiNose Announces Positive Results of Phase III Trial for OPN-375
From Business Wire News Releases
OptiNose to Present at Innovations in Healthcare Executive Forum
From Business Wire News Releases
OptiNose to Present at Nasal and Respiratory Drug Delivery Conferences
From Business Wire News Releases
OptiNose to Present at the 35th Annual Cowen Healthcare Conference
From Business Wire News Releases
OptiNose to Present at the 33rd Annual J.P. Morgan Healthcare Conference
From Business Wire News Releases
OptiNose Announces Publication of Pivotal Phase III Results for Investigational Migraine Treatment Developed by OptiNose Using Bi-Directional™ Breath Powered™ Technology
From Business Wire News Releases
OptiNose Completes Series C-1 Financing
Current Investors and Management Increase Support for OptiNose and the Company's Breakthrough New Product, OPN-375 
From PR Newswire
OptiNose Expands Senior Management Team with Three Key Appointments in Core Business Areas of Operations, Regulatory Affairs and Commercialization
From PR Newswire
OptiNose Announces Positive Results of COMPASS: A Head-to-Head Comparison of a New Migraine Treatment Using Bi-Directional™ Breath Powered™ Technology (AVP-825) versus Oral Sumatriptan
AVP-825, Using OptiNose's Patented Bi-Directional™ Breath Powered™ Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the Highest... 
From PR Newswire
OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
AVP-825 relies on novel closed palate Breath Powered™ drug delivery technology 
From PR Newswire
OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device
From Business Wire News Releases
New Hope for Migraine Sufferers: Optinose Nasal Delivery of Sumatriptan Proves as Effective as Invasive Subcutantaneous Injection
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.